Skip to main content
Premium Trial:

Request an Annual Quote

Waters, BD Biosciences Clontech, Definiens

Premium

Waters of Milford, Mass., has launched its MassPrep target plate for MALDI mass spectrometry. According to the company, the new targets allow on-plate preparation of protein digests and improve detection limits for low abundance peptides. Samples can be prepared manually or automatically using a

MassPrep Station

.

Waters also said that its ProteinLynx Global Server 2.0 mass spectrometry software suite is now available on the new IBM eServer pSeries 630, which is designed to run Linux and AIX operating systems.

 

BD Biosciences Clontech has released a protein extraction &

labeling kit

for preparing total protein extracts from biological samples. The extraction protocol is compatible with a variety of downstream analyses, including 2D gel electrophoresis, mass spectrometry, and immunoassays. It is also suitable to be used with BD Clontech’s Ab Microarray.

 

Definiens has launched version 2.0 of its 2D gel electrophoresis software, Proteomweaver. The update allows for automated analysis of gels and features an integrated database.

The software comes in two versions: The professional edition allows for up to 20 gels to be analyzed simultaneously, while the enterprise edition is amenable to high throughput work and can process up to 500 gels simultaneously. In less than 90 seconds, the software analyzes spots from 25 gel images, while filtering out artifacts, according to the company.

The software also offers support to spot picker devices from Bruker and Genetix, and a generic format enables any system to be integrated.

Definiens offers a two-day training course for new customers as well as support for the adaptation of the software to special requirements. A free test version can be downloaded at: http://www.definiens.com/ proteomweaver/downloads.htm.

The Scan

Study Finds Few FDA Post-Market Regulatory Actions Backed by Research, Public Assessments

A Yale University-led team examines in The BMJ safety signals from the US FDA Adverse Event Reporting System and whether they led to regulatory action.

Duke University Team Develops Programmable RNA Tool for Cell Editing

Researchers have developed an RNA-based editing tool that can target specific cells, as they describe in Nature.

Novel Gene Editing Approach for Treating Cystic Fibrosis

Researchers in Science Advances report on their development of a non-nuclease-based gene editing approach they hope to apply to treat cystic fibrosis.

Study Tracks Responses in Patients Pursuing Polygenic Risk Score Profiling

Using interviews, researchers in the European Journal of Human Genetics qualitatively assess individuals' motivations for, and experiences with, direct-to-consumer polygenic risk score testing.